Release date: 5 June 2024
Promoter – Financial Intermediary
ACCEPTABLE CORPORATE(S)Location
Description
The project supports the manufacturers of medicines, vaccines, diagnostics and medical devices to scale and optimise their supply mechanisms to be able to meet global demand. The project is funded by a master guarantee facility in favour of the Bill & Melinda Gates Foundation that shapes healthy markets for critical products to ensure accessibility and affordability to low- and middle-income populations.
Objectives
The operation is fully aligned with the priorities of Global Gateway as it supports the affordable access to medical products to tackle endemic, infectious and non-communicable diseases. It will also support the TEI on Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+). Ensuring affordability and accessibility to quality medical products in LMICs will contribute to the eradication of poverty, which is a pillar of NDICI across all regions.
Sector(s)
- Health - Human health and social work activities
Proposed EIB finance (Approximate amount)
EUR 52 million
Total cost (Approximate amount)
EUR 300 million
Environmental aspects
The Bank will require the intermediary institution to take all the requisite measures to ensure that the final beneficiaries undertake to implement and operate the sub-projects under the New Portfolio in compliance with the applicable national legislation and the relevant EIB Environmental and Social Standards.
Procurement
The Bank will require that implementation of the project will be done in accordance with the Bank's Guide to Procurement.
Status
Under appraisal - 24/05/2024
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).